Booked it secures £2.5 million investment from Calculus Capital
Innovative booking, marketing, CRM, and loyalty platform continues rapid growth
Innovative booking, marketing, CRM, and loyalty platform continues rapid growth
Hargreaves’ service will debut with a group of five VCTs including the Calculus VCT.
Calculus Investor Relations team members Matthew Moynes and Oliver Warren are joined by Investment Director and healthcare specialist Liz Klein to speak about EIS investing and how it can help mitigate a high tax burden.
Five years after entering the UK screen industries with the launch of the Creative Content EIS Fund, Calculus Capital CEO John Glencross reflects on how its investments in six indie production companies are performing.
The new Chancellor used the Autumn Statement as an opportunity to identify the critical role the EIS and VCT schemes play in creating a positive environment for UK entrepreneurship.
Laverock Therapeutics makes significant advances in its unique programmable gene silencing platform and announces pipeline focus on advanced therapies in oncology and genetic diseases.
Interview with Co-Head of Investments, Richard Moore. His role is to source and execute new deals, as well as advising a number of our portfolio companies.